We have previously suggested that treatment of hepatocellular carcinoma cell lines with recombinant "DKK1", a negative regulator of the Wnt pathway, may have an antitumor effect similar to that obtained with Pimozide, which acts by inhibiting the Wnt/beta-catenin pathway to reduce the proliferation of HepG2 and Hep3B lines according to V, Fako et al. [33]. Here, CTNNB1 is linked to hepatocellular carcinoma.